NEW OPPORTUNITIES FOR THE TREATMENT OF UNCONTROLLED ASTHMA IN RUSSIA

Abstract

Bronchial asthma (BA) is one of the most socially significant diseases of the respiratory system. The control over the symptoms of BA is achieved less than in 50% of cases even in highly developed countries. The reasons for the lack of control are heterogeneous. One of the most important reasons for the lack of control over symptoms BA in Russia is the unavailability of highly effective drugs for socially unprotected layers of the population. The solution of this problem could be the creation of Russian analogs for asthma treatment. A new Russian product - a combination of topical corticosteroids and DBA (fluticasone/salmeterol) - Suticase-native is going to appear on the Russian market. A study to assess the efficacy and safety of the new product was carried out on the base of three Russian scientific centers. This trail compared a new drug Suticase-nativ (salmeterol 50 mcg plus fluticasone propionate 250 mcg/dose), powder for inhalation (produced by «Nativ» - company, Russia), with its famous counterpart - a Seretide accuhaler diskus (salmeterol 50 mcg plus fluticasone propionate 250 mcg/ dose), powder for inhalation dosed, production Glaxo Operates UK Ltd, in patients with bronchial asthma. The results of the study showed high efficiency and safety of Suticase-Nativ, comparable to Seretide.